Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Kristen Spencer

9PUBLICATIONS
142CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

Sort by Publication Date:
|Jun 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

|Oct 31, 2025
Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Robert W Lentz, Julie Lang, Todd M Pitts

|Jun 30, 2025
A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.

Geoffrey Ku, Lin Shen, Farshid Dayyani

|Mar 06, 2025
Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.

Lakshmi Rajdev, Gentry G King, Christopher H Lieu

|Aug 10, 2023
The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.

Leontios Pappas, Islam Baiev, Stephanie Reyes

|Jun 30, 2023
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.

Milind Javle, Gentry King, Kristen Spencer

Pageof 2

Frequent Collaborators

2 joint publications

Christopher H Lieu

2 joint publications

Sunnie S Kim

2 joint publications

Milind M Javle

2 joint publications

Lipika Goyal

2 joint publications

S Lindsey Davis

2 joint publications

Farshid Dayyani

2 joint publications

Jochen K Lennerz

2 joint publications

Samuel J Klempner

1 joint publications

Gentry G King

1 joint publications

Anup Kasi

Frequent Collaborators

2 joint publications

Christopher H Lieu

2 joint publications

Sunnie S Kim

2 joint publications

Milind M Javle

2 joint publications

Lipika Goyal